Given that many POLE mutations observed in cancers are considered passenger alterations, additional investigations are needed to precisely characterize POLE mutations that enhance the immunogenicity of cancers and to elucidate whether defective replicative function in POLE is necessary or sufficient for ICI response. This evidence concerns the gene POLE and cancer.